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Abstract
Up to 90% of individuals with Huntington’s disease (HD), a progressive inherited 
neurodegenerative disease, experience apathy. Apathy is particularly debilitating because it is 
marked by a reduction in goal-directed behaviors, including self-care, social interactions, and 
mobility. The objective of this study was to examine relationships among apathy, functional status, 
physical function, cognitive function, behavioral status/emotional function, and health-related 
quality of life. Clinician-rated measures of physical, cognitive and behavioral function, including 
one clinician-rated item on apathy, and self-report measures of physical function, health-related 
quality of life, emotional, cognitive, and social function were collected in a single session from 
193 prodromal, 186 early stage manifest and 108 late stage manifest people with the HD mutation. 
Multiple linear regression models were used to examine which outcomes best predicted clinician-
rated apathy after controlling for disease stage. Greater apathy related to less independence, 
increased motor impairment, and more clinician-rated behavioral problems (i.e. anger, irritability, 
depression). Similarly, poorer self-reported health-related quality of life, greater chorea, greater 
upper and lower extremity dysfunction, greater speech and swallowing dysfunction, worse anxiety, 
depression and behavioral dyscontrol, worse cognitive function, and less satisfaction with social 
roles related to greater apathy. In summary, apathy related to physical, cognitive and behavioral 
dysfunction across disease stages. Future works should explore whether clinical interventions 
targeting different functional domains may have the potential to reduce apathy in this population.
Keywords
Huntington’s Disease; Apathy; Health-Related Quality of Life
Introduction
Huntington’s disease (HD) is a genetic, neurodegenerative disease characterized by motor, 
cognitive and behavioral changes. The behavioral changes with HD are particularly 
debilitating and relate to increased caregiver burden and reduced health-related quality of 
life (HRQOL).1,2 Apathy is one of the most disabling behavioral symptoms for patients and 
caregivers.3,4 Apathy affects up to 90% of individuals with HD4–6 and includes a marked 
lack of motivation, as well as reduced goal-directed behavior and action initiation, including 
self-care and mobility.7,8
Although the diagnosis for manifest HD relies heavily on motor manifestations, apathy may 
either precede motor difficulties or occur early in the course of the disease,10,11 thereby 
potentially providing an informative clinical marker of disease pathophysiology. Apathy 
may predict disease onset,9 and it correlates negatively with age of disease onset,10 and 
positively with the number of CAG repeats among those who are at risk for HD. Apathy 
increased in pre-manifest individuals over a three-year period,9,11 suggesting that it may be 
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useful for marking progression over time even prior to clinical diagnosis. In manifest 
disease, higher levels of apathy independently predict disability12 and correlate with longer 
disease duration,13 greater functional impairment14,15 and increased cognitive difficulty in 
attention, set-shifting, memory and sequencing.16 Apathy also relates to depression3 and 
irritability17 in HD, although its association to other behavioral symptoms remains to be 
clarified. Given the link between apathy and disability, as well as the presence of apathy 
across disease stages, apathy may be an important measure for tracking and monitoring 
disease progression in both early and late stage of HD.
While evidence suggests that higher levels of apathy relate to poorer functional, motor, 
cognitive and behavioral outcomes, as well as lower HRQOL in HD, a more comprehensive 
analysis of these associations is needed. Evidence from other neurodegenerative disease 
shows that apathy aligns with a greater caregiver burden, greater disability, and less 
rehabilitation success.18 Additionally, apathy is linked to poorer cognitive performance on 
executive function tasks, more severe motor impairments, and communication difficulties,19 
factors that have not yet been examined in HD. A better understanding of the associations 
among apathy and other measures in HD may provide insights into therapeutics or 
rehabilitation strategies to target apathy, which is especially important given the lack of 
existing recommendations or treatments for apathy. 20 Therefore, the objective of this study 
was to examine associations among apathy, functional status, physical function, cognitive 
function, behavioral status/emotional function and HRQOL. We hypothesized that apathy 
would increase across disease stages, and that greater apathy would be related to worse 
motor, cognitive and behavioral dysfunction and poorer HRQOL in persons with HD.
Methods
Data for the current analysis were collected from the baseline visit of a large cohort study 
that examined HRQOL in individuals with prodromal (positive gene test but no clinical 
diagnosis of HD), early- or late-stage HD (clinical diagnosis plus score of 7–13 for early- 
and 0–6 for late-HD on the TFC [described below]).21 Data collection occurred in 
conjunction with the PREDICT-HD study,22 a global cohort study with the purpose of 
assessing early symptoms of HD in prodromal participants.
Participant Visits
Participants were recruited through eight established HD clinics (CA, IA, IN, MD, MI, MN, 
MO, NJ), the National Research Roster for Huntington’s Disease, online medical record data 
capture systems,23 and through articles/advertisements in HD-specific newsletters and 
websites. Recruitment also included HD support groups and specialized nursing home units 
throughout the US. Participants completed an in-person assessment, and a computer-based 
self-report survey regarding HRQOL. Study visits lasted ~2 hours and participants were 
provided $40 compensation. All data were collected in accordance with local institutional 
review boards and participants provided informed consent prior to their participation in 
study activities.
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Measures
Clinician-Rated Assessments
Functional Status: Three measures from the Unified Huntington Disease Rating Scale 
(UHDRS) were administered to assess functional status: Total Functional Capacity (TFC),25 
the Functional Assessment scale (FA), and the Independence Scale. The TFC25 provides a 
clinician-rated assessment of ability to engage in work, manage finances, complete activities 
of daily living (ADLs), complete chores, and live independently. Scores range from 0–13 
with higher scores indicating better functioning. This measure was also used to determine 
HD staging (criteria highlighted above). The FA consists of 25 yes/no questions that assess 
the participant’s ability to perform tasks such as ADLs, engage in gainful employment, 
manage finances, or complete chores. Total scores range from 0–25 with higher scores 
indicating better functioning. The Independence Scale evaluates functional independence. 
Scores range from 0–100 with higher scores indicating better independence. All functional 
status measures were based on clinical interviews with the patient and an informant (when 
possible).
Physical Limitations: The Total Motor Score (TMS) from the UHDRS was used to assess 
motor impairment across 15 different domains, including chorea, dystonia, rigidity, 
oculomotor function, and bradykinesia. Total scores range from 0–124 with higher scores 
indicating more motor impairment.
Cognition: Three measures of cognition from the UHDRS were also administered: Verbal 
Fluency, Symbol Digit Modalities Test (SDMT), and Stroop (Color Naming, Word Reading, 
and Interference). Verbal Fluency provides a measure of executive function and language 
and requires participants to name as many words as they can that start with a particular letter 
within one minute. Scores reflect the total number of named words across three different 
letters. The SDMT provides a measure of psychomotor processing speed, working memory, 
and requires participants to match symbols with numbers according to a key that is provided 
at the top of the page. Total scores reflect the number of correctly matched symbols provided 
in 90 seconds. Scores range from 0 to 120 with higher scores indicating better psychomotor 
processing speed. The Stroop is an executive functioning task that involves selective 
attention, cognitive flexibility, cognitive inhibition and information processing speed. In this 
three-part task, participants are required to name patches of colored ink (Color Naming), 
read words (i.e., either red, green or blue; Word Reading), or name the color of written 
words that are written in the wrong color ink (i.e., the word red written in green ink; 
Interference). For each Stroop task, total scores reflect the number of correct responses 
provided in 45 seconds; higher scores indicate better executive function.
Behavioral Status: The Problem Behaviors Assessment short form (PBAs)24 was 
administered to evaluate eleven different behavioral problems and psychiatric symptoms 
(depression, suicidal ideation, anxiety, anger/aggression, irritability, apathy, obsessive 
compulsive behavior, perseverative thinking, delusions, hallucinations, and disoriented 
behavior). Severity scores for each behavior are rated from 0 (normal) to 4 (causing 
significant distress), while frequency scores are rated from 0 (never/almost never) to 4 (every 
day/at least once a day). The product of severity and frequency scores are calculated to 
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create a final score for each behavior which can range from 0 to 16, with higher scores 
indicating worse behavioral problems for each domain. Total scores reflect sum of the scores 
across all 11 behaviors, but given that apathy is our dependent variable of interest in the 
current analysis, the total PBAs scores included only the other 10 behaviors.
Self-Report Measures
Generic Measures of HRQOL
EQ-5D.26: The EQ-5D is a standardized instrument that measures health status across five 
domains of HRQOL: mobility, pain, ability to perform regular activities, ability to care for 
oneself, and anxiety/depression. The EQ5D includes both an Index scores (which ranges 
from 0 to 25 with higher scores indicating worse health outcomes) and a Health Scale score 
(which ranges from 0 to 100, with lower scores indicating worse overall health).
RAND-12.27: The Rand-12 is a HRQOL measure that asks about limitations in activities in 
relation to physical (pain, disability) and mental (depression, apathy, anxiety) health within 
the past month. Separate scores are calculated for physical and mental sections of the 
RAND-12, where raw scores range from 0 to 100. Final scores are calculated by subtracting 
the participant’s score from the average for their age-group, resulting in positive and 
negative difference scores.28 Positive scores reflect above average health for an individual’s 
age group, while negative scores reflect below average health for the participant’s age group.
28
World Health Organization Disability Assessment Schedule 2.0 (WHODAS).29: The 
WHODAS is a 12-item generic assessment of health and disability; it assesses mobility, 
cognition, self-care, participation, and activities. Total scores range from 0 to 48, with higher 
scores indicating more functional limitations.
Physical Ability Measures—Several physical ability measures from Quality of Life in 
Neurological Disorders (Neuro-QoL)30 and the Huntington Disease Quality of Life 
(HDQLIFE) measurement system21 were also completed. The Neuro-QoL is designed to 
evaluate HRQOL in individuals with neurological conditions,30 whereas HDQLIFE was 
developed to examine HRQOL domains specific to those living with HD. We administered 
Neuro-QOL Lower Extremity Functioning (mobility), Neuro-QOL Upper Extremity 
Functioning (ability to use hands and arms to perform tasks of ADL and fine motor 
movements), HDQLIFE Speech Difficulties31 (the ability to speak and be understood in a 
variety of social situations), HDQLIFE Swallowing Difficulties31 (the ability to swallow and 
fears related to choking), and HDQLIFE Chorea32 (the effects of chorea on task 
completion). Each item bank is scaled on a T-metric with a mean of 50 and a standard 
deviation of 10 (the referent group for Neuro-QOL are other individuals with neurological 
conditions, whereas the referent group for HDQLIFE are other individuals with HD), with 
higher scores on Neuro-QoL domains indicating better functioning and high scores on 
HDQLIFE measures indicating poorer physical functioning.
Emotional Status Measures—Study participants also completed several measures of 
emotional function from Neuro-QoL,30 HDQLIFE,21 and the Patient Reported Outcomes 
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Measurement Information System (PROMIS).33 Participants completed Neuro-QoL 
Emotional/Behavioral Dyscontrol (irritability, impatience, and impulsiveness), Neuro-QoL 
Positive Affect and Well-being (perceived sense of purpose and meaning), Neuro-QoL 
Stigma (perceived negativity of others towards the participant as a result of their symptoms), 
HDQLIFE Concern with Death and Dying34 (end of life issues including fear of death and 
end of life planning), HDQLIFE Meaning and Purpose34 (sense of meaning and making the 
most of the time they have left), PROMIS Anger, PROMIS Anxiety, and PROMIS 
Depression. Similar to above, each item bank is scaled on a T-metric with a mean of 50 and 
a standard deviation of 10 (the referent group for Neuro-QOL are other individuals with 
neurological conditions, whereas the referent group for HDQLIFE are other individuals with 
HD, and the referent group for PROMIS are individuals in the general population), with 
higher scores indicating worse emotional functioning (except for Neuro-QoL Positive Affect 
and Well-Being and HDQLIFE Meaning and Purpose, where higher scores indicate better 
functioning).
Cognitive Ability Measures—Two measures of cognition were administered from 
Neuro-QoL:30 Neuro-QoL Applied Cognition-Executive Function (cognitive planning and 
organizing) and Neuro-QoL Applied-Cognition-General Concerns (perceived difficulty in 
concentration and memory). Measures are scored on a T-metric with a mean of 50 and a 
standard deviation of 10 (the referent group for these measures are other individuals with 
neurological conditions), with higher scores indicating better cognitive function.
Social Function Measures—Two measures of social function were administered from 
Neuro-QoL:30 Satisfaction with Social Roles and Activities (SATSRA; one’s contentment in 
obligations pertaining to family, friends, and work) and Ability to Participate in Social Roles 
and Activities (SRA; one’s involvement in obligations pertaining to family, friends, and 
work). These item banks are scaled on a T-metric with a mean of 50 and a standard deviation 
of 10 (the referent group are other individuals with neurological conditions), with higher 
scores indicating better social function.
Statistical Analyses
Prior to examining the associations between clinician-rated and self-report variables and 
PBAs Apathy scores, we first compared the levels of PBAs Apathy across the three staging 
groups (prodromal, early- or late-stage HD) using one-way, two-tailed, analysis of variance. 
Next, we computed a series of multiple linear regressions using PBAs Apathy as the 
outcome and each of the clinician-rated and self-report variables as independent measures.
Clinician-Rated Apathy—A one-way two-tailed Analysis of Variance (ANOVA) was 
conducted to determine differences in PBAs Apathy scores between the three HD staging 
groups.
Creating Composite Scores—To minimize the number of regression models used, 
composite scores for each of the nine aforementioned domains (clinician-rated physical 
ability (TMS), clinician-rated functioning, clinician-rated cognition, clinician-rated 
behavioral status, generic HRQOL, self-report physical ability, self-report emotional status, 
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self-report cognition, and self-report social function) were created for participants with 
complete data. Scores on each individual measure (i.e., Verbal Fluency, Stroop, and Symbol 
Digits Modalities Test for clinician-rated cognition; UHDRS Independence scale, UHDRS 
Functional Assessment, and UHDRS Total Functional Capacity for clinician-rated 
functioning; the 11 behaviors on the PBAs for clinician-rated mental health; the UHDRS 
Total Motor Scale for clinician-rated physical ability; Neuro-QoL Emotional and Behavioral 
Dyscontrol, Neuro-QoL Positive Affect and Well-Being, Neuro-QoL Stigma, HDQLIFE 
Concern with Death and Dying, HDQLIFE Meaning and Purpose, PROMIS Depression, 
PROMIS Anxiety, and PROMIS Anger for self-reported emotional status; HDQLIFE 
Chorea, HDQLIFE Speech Difficulties, HDQLIFE Swallowing Difficulties, Neuro-QoL 
Lower Extremities, and Neuro-QoL Upper Extremities for self-reported physical ability; 
Neuro-QoL Ability to Participate in Social Roles and Activities and Neuro-QoL Satisfaction 
with Social Roles and Activities for social functioning; Neuro-QoL Executive Functioning 
and Neuro-QoL General Concerns for self-reported cognition; the WHODAS, RAND-12, 
and EQ-5D measures for generic HRQOL), were first recoded to ensure that higher scores 
indicated better outcomes. Next, these individual scores were then standardized to have a 
mean of 0 and standard deviation of 1. Then, these standardized scores were summed for 
each respective composite score (i.e., clinician-rated cognition,, clinician-rated functioning, 
clinician-rated behavioral status, self-report emotional status, and clinician-rated physical 
ability, self-reported emotional status, self-report physical ability, self-report social function, 
self-reported cognition, generic HRQOL). The sum scores within each of the nine composite 
groups were then scaled with a mean of 0 and standard deviation of 1 so that each composite 
score was on the same scale.
Multiple Linear Regression Models
Each of the nine composite scores were entered into separate multiple linear regression 
models (two-tailed tests of significance at p<.05), where the composite measure was the 
predictor, staging and clinician rated depression were covariates (except when depression 
was included as part of the composite score [i.e., analysis examinging Clinician Mental 
Health]), and apathy was the outcome. R2 values were used to determine which variables 
accounted for the most variance in apathy scores. We considered R2 values between .01 and .
08 to be small or minimal effect sizes, values between .09 and .24 were considered 
moderate, and effect sizes greater than .25 to be large. These R2 values were then compared 
using Fisher’s R to Z transformation35, which sets correlation coefficient values onto a 
normal distribution scale with confidence intervals that can be statistically evaluated (while 
similar, this is not to be confused with the Fisher’s Z Distribution). Finally, the Root Mean 
Square Error (RMSE), which is the standard deviation of the residuals, was calculated as an 
additional assessment of model fit.
Results
One hundred and ninety-three (193) prodromal, 187 early-stage, and 91 late-stage manifest 
HD participants were assessed (Table 1). The three groups differed by age (F[2, 468] = 43.3; 
p<.0001), which was expected given the progressive nature of HD. The prodromal 
participants were approximately 8 years younger than the early stage group and 13 years 
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younger than the late stage group. The prodromal participants also had significantly more 
years of education (F[2, 434]= 15.6; p<.0001) than both the early and late stage groups. The 
groups did not significantly differ for gender (X2= 3.60; p=.17). The groups did significantly 
differ for race (Fisher’s Exact p<.0001); the prodromal group did not include African 
Americans, whereas the early and late stage groups did. The groups also differed for marital 
status (Fisher’s Exact p<.0001); the prodromal group did not include any widowed 
individuals, and had fewer divorced/separated individuals than the other two groups.
Across the three HD groups, average PBAs apathy score was 2.5 (SD=4.0). The prodromal 
group had an average score of 1.4 (SD=2.9), which was significantly lower than both the 
early-stage (mean=3.0; SD=4.1) and late-stage (mean=3.9; SD=5.0) group (F[2,468]=14.9; 
p<.0001). Early and late-stage scores did not significantly differ. Therefore, all models were 
adjusted for stage of disease.
Multiple Linear Regression Models
Table 2 highlights findings from the multiple linear regression models, after controlling for 
HD disease stage. For clinician-rated assessments, better behavioral status (t[1]= −12.77; p<.
0001) was associated with better apathy scores (Table 2). There was no association between 
apathy and clinician-rated cognition (t[1]= −0.85; p=.3955), clinician-rated functioning 
(t[1]= −1.15; p=.2504), nor clinician-rated physical ability (t[1]=−0.86; p=.3928). The 
adjusted R2 value for behavioral status was large at 0.30, while the adjusted R2 values for 
physical ability, functioning, and cognition were all moderate (0.20, 0.14 and 0.18, 
respectively).
For self-reported HRQOL, better scores on the generic composite measure (t[1]= −2.33; p=.
0201), emotional status (t[1]= −3.74; p<.0001), cognition (t[1]= −5.04; p<.0001), and social 
functioning (t[1]= −6.25; p<.0001) were all significantly associated with better apathy 
outcomes (Table 2). Self-reported physical ability (t[1]= −1.46; p=.1445) was not associated 
with apathy. Adjusted R2 values for generic HRQOL (.21), physical ability (0.19), emotional 
status (0.22), cognition (0.24) were moderate, and social function (0.26) had a large effect 
size.
Comparisons of R2 Effect Sizes
The Fisher’s R to Z transformations revealed significant differences between R2 values for 
each of the 8 composite measures. The composite score with the highest R2 value was 
clinician-rated problem behaviors (R2=0.30; Table 2). The R2 value for clinician-rated 
problem behaviors did not significantly differ from generic HRQOL (R2=0.21; z = 1.79; p=.
0735). The R2 value for clinician-rated problem behaviors was, however, significantly higher 
than clinician-rated physical functioning (R2=0.20; z=2.03; p=.04), clinician rated 
functioning (R2=0.14; z=2.99; p=.0028), clinician rated cognition (R2=0.18; z=2.18; p=.
0324), and self-reported physical functioning (R2=0.19; z=2.21; p=.0271).. Additionally, 
self-reported social functioning (R2=0.26) had a higher adjusted R2 value than clinician 
rated functioning (R2=0.14; z=2.26; p=.0238). Generic HRQOL, self-report emotion, and 
self-reported cognition had similar adjusted R2 values with all other composite measures.
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Discussion
This study examined associations among apathy and functional status, physical ability, 
cognition, behavioral status/emotional health and HRQOL in participants with prodromal 
and manifest HD. As expected, apathy levels differed by stage of disease, with individuals in 
the prodromal group demonstrating less apathy than participants in the early and late stage 
groups. These findings support other research that suggests that apathy increases with HD 
progression.10
In our cohort, worsened functional capacity and behavioral status were associated with 
higher levels of apathy. In addition, apathy related to almost all self-reported assessments of 
these same constructs, as well as with cognition. These findings are largely consistent with 
the extant literature in HD, which indicates that greater apathy relates to lower functional 
status and reduced independence14,15,36. Our findings are somewhat discrepant from other 
research in HD, PD, and AD suggesting that increased apathy relates to worse objectively 
measured cognitive function.16,19 While previous research shows correlations between 
objective cognition and apathy, our study did not find such associations. One explanation for 
this is that our study measured different domains of cognitive function than previous studies. 
The cognitive measures used in this study (Stroop, Verbal Fluency, and SDMT) primarily 
measure executive functioning, processing speed, attention, and language, whereas other 
studies have utilized the Mini-Mental State Exam 19, which measures orientation, 
registration, calculation, and recall or the Mattis Dementia Rating Scale16, which measures 
initiation, construction, conceptualization, and memory. Therefore, it is possible that 
different domains of objective cognition have different associations with apathy. Although 
apathy did not correlate with objective assessments of cognition, there was a significant 
association between apathy and self-reported cognitive function. One explanation for this 
discrepancy is that subjective measures of memory and cognition are often stronger 
indicators of overall emotional distress, rather than an objective evaluation of cognition.38 
Additionally, anosognosia, or symptom unawareness, is common in HD and therefore may 
play a role in this discrepancy; previous studies have shown that participants with greater 
cognitive deficits are more likely underreport cognitive symptoms.39
Although little is known about the association between apathy and emotional and behavioral 
status in HD, our results are consistent with prior work showing associations among apathy, 
depression and irritability.3,17 In our cohort, clinician-rated behavioral problems, self-
reported emotional problems/symptoms, and lower levels of positive affect/well-being and 
feelings of meaning/purpose were all associated with higher levels of apathy.
With regard to HRQOL, greater apathy related to worse overall HRQOL, and less social 
satisfaction and participation. Such findings support previous work in HD40,41 and PD.19 
This study builds upon prior work by including five different measures of HRQOL in a large 
cohort of individuals with HD across stages of disease.
To our knowledge, no existing clinical treatments have targeted the reduction of apathy. Our 
results, however, identify associations of apathy, such as depression and behavioral 
dyscontrol that may be manageable with pharmacological and non-pharmacological 
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interventions. These results align with studies in PD and AD, suggesting that many 
associations with apathy may be common among neurodegenerative conditions. As 
depression and behavioral dyscontrol are quite common in HD, future work is needed to 
determine if interventions that target these specific domains may vicariously reduce apathy 
as a result.
Although this study highlights a number of important findings with regard to apathy in HD, 
it is also important to acknowledge several study limitations. First, findings are based on a 
convenience sample of individuals with HD, and thus may not represent the HD population 
at large. Second, although apathy is considered a multidimensional construct,7,8 this study 
utilized a single clinician-rated item of apathy and did not include a self-report measure of 
apathy. Future work should include a more comprehensive assessment of apathy that 
includes multiple aspects of motivation. In addition, participants completed the clinician-
rated assessments and self-report measures within a two-week window and not necessarily 
within the same session, weakening analyses focused on the associations between clinician-
rated apathy and self-report assessments for some participants.
Conclusions
Our data suggest that apathy relates to functional status, physical function, self-report 
cognitive function, behavioral status/emotional function, and HRQOL in HD. These findings 
are consistent with work in other neurodegenerative diseases and suggest that clinical 
interventions should consider targeting apathy, since it appears to be rather pervasive in 
terms of affecting multiple aspects of functioning and HRQOL. In addition, future work 
should focus on further characterizing the different aspects of apathy that have been 
established in other neurological diseases.
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Table 1
Demographics of the three staging groups
Variable Prodromal (N=193) Early (N=187) Late (N=91) All (N=471)
Age(Years)*
M (SD) 43.1 (12.1) 51.5 (12.8) 56.2 (10.4) 48.9 (13.1)
Gender (%)
Female 64.8 55.6 57.1 59.7
Male 35.2 44.4 42.9 40.3
Race (%)*
White 98.5 95.7 94.5 96.6
African American 0.0 1.6 5.5 1.7
Other 1.0 2.7 0.0 1.5
Not Provided 0.5 0.0 0.0 0.2
Ethnicity (%)
Not Hispanic or Latino 93.3 92.5 97.2 93.8
Hispanic or Latino 1.0 4.3 0.9 2.3
Not Provided 5.7 3.2 1.9 3.9
Education (# of years)*
M (SD) 16.0 (2.8) 14.8 (2.8) 14.2 (2.6) 15.2 (2.9)
Marital Status (%)*
Single, Never Married 14.4 15.7 8.2 13.8
Married 69.5 56.2 67.1 63.8
Separated/Divorced 13.9 21.4 22.4 18.4
Widowed 0.0 2.8 2.3 1.6
Living with Partner 2.2 3.9 0.0 2.4
CAG Repeats
M (SD) 42.1 (2.5) 43.2 (3.9) 43.3 (2.8) 43.0 (3.4)
Note.
*indicates significant group differences.
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